Simulations Plus Partners with Clinical-Stage Biotech Company to Develop Novel Dosing Models
September 04 2019 - 8:30AM
Business Wire
New intra-articular injection route will
expand the suite of drug delivery options available in
GastroPlus®
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of
modeling and simulation solutions for the pharmaceutical,
biotechnology, chemicals, and consumer goods industries, today
announced that it has entered into a new funded collaboration with
a clinical-stage biotechnology company to develop an
intra-articular (IA) delivery model in the GastroPlus® Additional
Dosage Routes Module.
“We are very pleased to announce this collaboration, which will
enhance the GastroPlus physiologically based biopharmaceutics
(PBBM)/physiologically based pharmacokinetic (PBPK) model for drug
dosing into joints through IA injection products,” said Viera
Lukacova, director of Simulation Sciences for Simulations Plus.
“Leveraging the data and scientific expertise of our partner, we
intend to incorporate a mechanistic model for different species and
population groups that will allow for efficient evaluation of IA
injection strategies. This will provide a framework to support
similar approaches for other drugs.”
John DiBella, Lancaster division president for Simulations Plus,
added: “These agreements help to extend the industry leading
capabilities of our software tools, while at the same time
increasing the investment that Simulations Plus contributes toward
new research initiatives. Also, similar to other collaborations
which funded development of the numerous dosing models in the
GastroPlus Additional Dosage Routes Module, Simulations Plus
maintains the right to license the new functionality to all
clients, creating additional revenue streams. We look forward to
continued interactions with our partners to drive advances to the
GastroPlus platform and share the outcomes with the global
scientific community.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug
discovery/development software and a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury, drug-induced kidney injury, and
nonalcoholic fatty liver disease. Our software is used to conduct
drug research by major pharmaceutical, biotechnology, chemical,
consumer goods companies and regulatory agencies worldwide. Our
innovations in integrating new and existing science in medicinal
chemistry, computational chemistry, pharmaceutical science,
biology, and physiology into our software have made us the leading
provider for physiologically based pharmacokinetic modeling and
simulation. Visit us online www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation
Reform Act of 1995 – With the exception of historical
information, the matters discussed in this press release are
forward-looking statements that involve a number of risks and
uncertainties. Words like “believe,” “expect” and “anticipate” mean
that these are our best estimates as of this writing, but that
there can be no assurances that expected or anticipated results or
events will actually take place, so our actual future results could
differ significantly from those statements. Factors that could
cause or contribute to such differences include, but are not
limited to: our ability to maintain our competitive advantages,
acceptance of new software and improved versions of our existing
software by our customers, the general economics of the
pharmaceutical industry, our ability to finance growth, our ability
to continue to attract and retain highly qualified technical staff,
our ability to identify and close acquisitions on terms favorable
to the Company, and a sustainable market. Further information on
our risk factors is contained in our quarterly and annual reports
and filed with the U.S. Securities and Exchange Commission.
Follow us on Twitter | LinkedIn | YouTube
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190904005019/en/
Simulations Plus Investor Relations
Ms. Renee Bouche 661-723-7723 renee@simulations-plus.com
Hayden IR Mr. Cameron Donahue
651-653-1854 cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024